<DOC>
	<DOCNO>NCT00651313</DOCNO>
	<brief_summary>The purpose study determine whether lidocaine vaginal gel safe effective prevent reduce severity dysmenorrhea ( painful menstrual period ) compare placebo ( inactive gel ) .</brief_summary>
	<brief_title>Efficacy Safety Study Lidocaine Vaginal Gel Recurrent Dysmenorrhea ( Painful Periods )</brief_title>
	<detailed_description>The primary objective study evaluate efficacy 10 % ( 150 mg ) lidocaine gel compare placebo reduce severity onset primary dysmenorrhea woman recurrent dysmenorrhea . The secondary objective study follow : - ass safety 10 % ( 150 mg ) lidocaine gel compare placebo - evaluate electrocardiogram ( ECGs ) potentially significant QT change approximate peak lidocaine plasma concentration 4 day dose 10 % ( 150 mg ) lidocaine gel .</detailed_description>
	<mesh_term>Dysmenorrhea</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>1 . Experiences primary dysmenorrhea require pain medication moderatetosevere pain ( measure 4point categorical rating scale ) subject 's report least four previous six menstrual cycle . 2 . Has history primary dysmenorrhea onset within 4 year menarche . 3 . Has regular menstrual cycle ( i.e . onset menses predictable within 1 2 day month ) 3 month period precede enrollment . If subject regular cycle past 12 month single cycle regular within 3 month period precede enrollment , subject may enrol investigator discretion consultation sponsor . 4 . Taking strength type hormonal contraception monthly cycle least previous 6 month prior screen plan remain hormonal contraception duration participation study acceptable method birth control include surgical sterilization ( i.e . bilateral tubal ligation , partner vasectomy ) , doublebarrier method , total abstinence ( discretion investigator case age , career , lifestyle , sexual orientation patient ensure compliance ) . 5 . Is tampon user and/or must willing use tampon throughout study dose period . 6 . Age 18 40 year ( inclusive ) . 7 . Has Body Mass Index ( BMI ) â‰¤ 35 kg/m2 . 8 . Able understand willing complete efficacy evaluation . 9 . Able speak understand English , must give write informed consent study . 1 . Unable , opinion Investigator , comply fully study requirement . 2 . Experiencing pelvic pain think associate primary dysmenorrhea , chronic pelvic pain occur time exclusively menses and/or dyspareunia . 3 . Experiencing dysmenorrhea symptom effect think effect ( least part ) secondary cause dysmenorrhea , uterine fibroid , endometriosis , and/or currently symptomatic ovarian cyst . 4 . Experienced dysmenorrhea require , opinion subject , use analgesic medication four previous six menstrual episode . 5 . Has dysmenorrhea refractory treatment commonly use analgesic medication treatment menstrual pain ( e.g. , ibuprofen naproxen sodium ) . 6 . Use Class I antiarrhythmic drug . 7 . Currently use contraceptive injection , implant , extend cycle OC ( hormonal contraceptive cycle consist 28 day active hormone ) . 8 . Pregnant breastfeeding . 9 . Participated clinical trial 30 day time last dosing prior study time provide consent study . 10 . Previously randomize study . 11 . A history allergic hypersensitivity significant intolerance ( include angioedema , urticaria , bronchospasm , rhinitis ) relate treatment medication use study . 12 . A history past ongoing clinically significant disease , illness , disorder , opinion Investigator , make subject unsuitable study participation include active vaginal , vulvar , cervical lesion . 13 . Laboratory abnormality , opinion Investigator , could contraindicate study participation liver function test &gt; 1.5 time upper limit normal ( At Investigator 's discretion , laboratory test may repeat verification . ) 14 . A history , within past 4 year , ongoing significant psychiatric illness , opinion Investigator , make subject unsuitable study participation . 15 . A history chronic analgesic tranquilizer use drug abuse include alcohol within 6 month provide consent study . 16 . Regular use concomitant medication might confound efficacy and/or safety assessment , opinion Investigator , include , limited , follow : psychotropic drug , antidepressant , sedativehypnotics , sedate antihistamine , tranquilizer 24 hour five halflives prior provide inform consent 24 hour final treatment cycle . Selective serotonin reuptake inhibitor ( SSRIs ) , serotonin norepinephrine reuptake inhibitor ( SNRIs ) , St. John 's Wort permit indication pain subject stable dose least 2 week provide consent study agree remain stable dose throughout course study . 17 . Unwilling use medication allow study treatment dysmenorrhea , i.e. , study drug rescue medication . 18 . Any ongoing vaginal infection require intravaginal treatment . 19 . A history toxic shock syndrome ( TSS ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Dysmenorrhea</keyword>
	<keyword>Periods</keyword>
	<keyword>Menstrual</keyword>
	<keyword>Primary dysmenorrhea woman recurrent dysmenorrhea</keyword>
</DOC>